The University of Texas MD Anderson Cancer Center (US)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
115
Publications
2355
Citations
57411
i10-index
809
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
International Consensus Classification of Myeloid ... | 2022 | 2752 |
Results of intensive chemotherapy in 998 patients ... | 2006 | 607 |
Efficacy, Safety, and Biomarkers of Response to Az... | 2018 | 574 |
Ibrutinib and Venetoclax for First-Line Treatment ... | 2019 | 507 |
Phase 1/2 study of the combination of 5-aza-2′-deo... | 2006 | 468 |
Clinical experience with the <scp>BCL</scp>2‐inhib... | 2017 | 441 |
Chronic myeloid leukemia: 2018 update on diagnosis... | 2018 | 418 |
Chronic myeloid leukemia: 2020 update on diagnosis... | 2020 | 412 |
Inotuzumab ozogamicin, an anti-CD22–calecheamicin ... | 2012 | 412 |
Intensive chemotherapy does not benefit most older... | 2010 | 401 |
Elias Jabbour is a researcher with 2355 publications and 57411 citations. They are affiliated with The University of Texas MD Anderson Cancer Center. Their research focuses on . With an h-index of 115, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Elias Jabbour and 250M+ other papers.
Citations per publication by year